🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

161 results for “Janssen-Cilag International N.V.” Clear

  1. DEXAMETHASONE SODIUM PHOSPHATE, VELCADE 3.5 mg powder for solution for injection, DARATUMUMAB, CYCLOPHOSPHAMIDE

    Janssen-Cilag International N.V.

    Amyloid Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  2. Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Dexamethason 4 mg JENAPHARM®, teclistamab, teclistamab, Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 2 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Pomalidomide, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Im

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  3. Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, JNJ-42756493, Gemcitabine 2 g Powder for Solution for Infusion, JNJ-42756493, JNJ-42756493, Mitomycin medac 1 mg/ml Pulver zur Herstellung einer Injektions- bzw. Infusionslösung oder einer Lösung zur intravesikalen Anwendung

    Janssen-Cilag International N.V.

    Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions

    phase 2 small molecule active

    1 trial

  4. Golimumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Placebo for Guselkumab, Golimumab and JNJ-78934804, JNJ-78934804

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  5. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Placebo to Guselkumab and Golimumab and JNJ-78934804, Golimumab, JNJ-78934804

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  6. INC280, INC280, JNJ-61186372

    Janssen-Cilag International N.V.

    Unresectable Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL , IRINOTECAN , Fluorouracil Hikma 50 mg/ml Injektionslösung, Ribofolin® 10 mg/ml Injektionslösung, JNJ-61186372, OXALIPLATIN , CALCIUM FOLINATE , JNJ-61186372, BENDAFOLIN 10 mg/ml Injektionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    Janssen-Cilag International N.V.

    Advanced or Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  8. JNJ-17000139, JNJ-63723283, JNJ-63723283

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma of the Bladder

    phase 2 small molecule active

    1 trial

  9. JNJ-17000139, JNJ-63723283, JNJ-63723283

    Janssen-Cilag International N.V.

    Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder

    phase 2 small molecule active

    1 trial

  10. JNJ-42756493, JNJ-42756493, JNJ-42756493

    Janssen-Cilag International N.V.

    Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.

    phase 2 small molecule active

    1 trial

  11. JNJ-54767414, Lenalidomide Accord 25 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Dexamethasone Tablets BP 2.0mg, FLUDARABINE , Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, JNJ-68284528, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Accord 15 mg hard c

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  12. JNJ-61186372, JNJ-63723283, JNJ-63723283

    Janssen-Cilag International N.V.

    Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. JNJ-64407564, RoActemra 20 mg/mL concentrate for solution for infusion, JNJ-64407564, JNJ-64407564, Tyenne 20 mg/ml concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Tyenne 20 mg/ml concentrate for solution for infusion, JNJ-64407564

    Janssen-Cilag International N.V.

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  14. JNJ-68284528, CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusion

    Janssen-Cilag International N.V.

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  15. JNJ-73841937, JNJ-61186372

    Janssen-Cilag International N.V.

    Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. JNJ-73841937, Montelukast Sodium Tablets, Dexamethason 4 mg JENAPHARM®, Methotrexat-Ebewe, 10mg/ml, roztwór do wstrzykiwań, JNJ-61186372, Methotrexate

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. JNJ-73841937, PEMETREXED , JNJ-61186372, CARBOPLATIN

    Janssen-Cilag International N.V.

    Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.

    phase 2 small molecule active

    1 trial

  18. JNJ-79635322, JNJ-79635322

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  19. JNJ-80202135, JNJ-80202135, Saline, 0.9% Sodium Chloride Solution for Injection

    Janssen-Cilag International N.V.

    Active Idiopathic Inflammatory Myopathies (IIM)

    phase 2 small molecule active

    1 trial

  20. JNJ-81241459, JNJ-81241459 200mg, placebo tablet, JNJ-81241459, JNJ-81241459 50mg, placebo tablet

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  21. JNJ-88545223, JNJ-88545223, JNJ-88545223 Placebo

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  22. JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  23. Kenacort-A 40, suspensie voor injectie 40 mg/ml, JNJ-81201887, Placebo to match Prednisone 20mg, 5mg, JNJ-81201887, Prednison acis 20 mg, Tabletten, Prednison acis 5 mg, Tabletten

    Janssen-Cilag International N.V.

    Geographic Atrophy

    phase 2 small molecule active

    1 trial

  24. Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, IMBRUVICA 140 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 15 mg hard capsules, JNJ-54179060, Lenalidomide Accord 2.5 mg hard capsules, Ruxi

    Janssen-Cilag International N.V.

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources